Works about EMTRICITABINE

Results: 411
    1

    Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.

    Published in:
    2020
    By:
    • Sculier, Delphine;
    • Wandeler, Gilles;
    • Yerly, Sabine;
    • Marinosci, Annalisa;
    • Stoeckle, Marcel;
    • Bernasconi, Enos;
    • Braun, Dominique L.;
    • Vernazza, Pietro;
    • Cavassini, Matthias;
    • Buzzi, Marta;
    • Metzner, Karin J.;
    • Decosterd, Laurent A.;
    • Günthard, Huldrych F.;
    • Schmid, Patrick;
    • Limacher, Andreas;
    • Egger, Matthias;
    • Calmy, Alexandra;
    • and the Swiss HIV Cohort Study (SHCS);
    • Swiss HIV Cohort Study (SHCS)
    Publication type:
    journal article
    2
    3
    4
    5
    6

    Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men.

    Published in:
    JAMA Network Open, 2020, v. 3, n. 12, p. e2030806, doi. 10.1001/jamanetworkopen.2020.30806
    By:
    • McManus, Hamish;
    • Grulich, Andrew E.;
    • Amin, Janaki;
    • Selvey, Christine;
    • Vickers, Tobias;
    • Bavinton, Benjamin;
    • Zablotska, Iryna;
    • Vaccher, Stephanie;
    • Jin, Fengyi;
    • Holden, Joanne;
    • Price, Karen;
    • Yeung, Barbara;
    • Cabrera Quichua, Gesalit;
    • Ogilvie, Erin;
    • McNulty, Anna;
    • Smith, David;
    • Guy, Rebecca
    Publication type:
    Article
    7
    8
    9
    10
    11

    Prepared, Protected, EmPowered (P3): Primary Results of a Randomized Controlled Trial Using a Social Networking, Gamification, and Coaching App to Promote Pre-exposure Prophylaxis (PrEP) Adherence for Sexual and Gender Minority (SGM) Youth Living in the United States

    Published in:
    AIDS & Behavior, 2025, v. 29, n. 2, p. 652, doi. 10.1007/s10461-024-04547-0
    By:
    • Hightow-Weidman, Lisa B.;
    • Rainer, Crissi;
    • Schader, Lindsey;
    • Rosso, Matthew T.;
    • Benkeser, David;
    • Cottrell, Mackenzie;
    • Tompkins, Lauren;
    • Claude, Kristina;
    • Stocks, Jacob B.;
    • Yigit, Ibrahim;
    • Budhwani, Henna;
    • Muessig, Kathryn E.
    Publication type:
    Article
    12

    Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.

    Published in:
    AIDS & Behavior, 2025, v. 29, n. 1, p. 64, doi. 10.1007/s10461-024-04490-0
    By:
    • Mussini, Cristina;
    • Cazanave, Charles;
    • Adachi, Eisuke;
    • Eu, Beng;
    • Alonso, Marta Montero;
    • Crofoot, Gordon;
    • Chounta, Vasiliki;
    • Kolobova, Irina;
    • Sutton, Kenneth;
    • Sutherland-Phillips, Denise;
    • Urbaityte, Rimgaile;
    • Ehmann, Alice;
    • Scherzer, Jenny;
    • de los Rios, Patricia;
    • D'Amico, Ronald;
    • Spreen, William;
    • van Wyk, Jean
    Publication type:
    Article
    13
    14
    15

    Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).

    Published in:
    AIDS & Behavior, 2022, v. 26, n. 12, p. 4107, doi. 10.1007/s10461-022-03736-z
    By:
    • Mayer, Kenneth H.;
    • Yuhas, Krista;
    • Amico, K. Rivet;
    • Wilkin, Timothy;
    • Landovitz, Raphael J.;
    • Richardson, Paul;
    • Marzinke, Mark A.;
    • Hendrix, Craig. W;
    • Eshleman, Susan H.;
    • Cottle, Leslie M.;
    • Marcus, Cheryl;
    • Chege, Wairimu;
    • Rinehart, Alex R.;
    • Rooney, James F.;
    • Andrew, Philip;
    • Salata, Robert A.;
    • Magnus, Manya;
    • Farley, Jason E.;
    • Liu, Albert Y.;
    • Frank, Ian
    Publication type:
    Article
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28

    Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort.

    Published in:
    Viruses (1999-4915), 2023, v. 15, n. 6, p. 1222, doi. 10.3390/v15061222
    By:
    • Lazzaro, Alessandro;
    • Bianchini, Diana;
    • Gentilini Cacciola, Elio;
    • Mezzaroma, Ivano;
    • Falciano, Mario;
    • Andreoni, Carolina;
    • Fimiani, Caterina;
    • Santinelli, Letizia;
    • Maddaloni, Luca;
    • Bugani, Ginevra;
    • Ceccarelli, Giancarlo;
    • Mastroianni, Claudio Maria;
    • d'Ettorre, Gabriella
    Publication type:
    Article
    29

    Trajectories of CD4 + /CD8 + T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study.

    Published in:
    Viruses (1999-4915), 2022, v. 14, n. 11, p. 2315, doi. 10.3390/v14112315
    By:
    • Taramasso, Lucia;
    • Falletta, Antonio;
    • Ricci, Elena;
    • Orofino, Giancarlo;
    • Squillace, Nicola;
    • Menzaghi, Barbara;
    • De Socio, Giuseppe Vittorio;
    • Molteni, Chiara;
    • Pellicanò, Giovanni Francesco;
    • Gulminetti, Roberto;
    • Madeddu, Giordano;
    • Sarchi, Eleonora;
    • Vichi, Francesca;
    • Celesia, Benedetto Maurizio;
    • Bonfanti, Paolo;
    • Di Biagio, Antonio
    Publication type:
    Article
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48

    Effectiveness, safety, and patient‐reported outcomes of emtricitabine/tenofovir alafenamide‐based regimens for the treatment of HIV‐1 infection: Final 24‐month results from the prospective German TAFNES cohort study.

    Published in:
    HIV Medicine, 2025, v. 26, n. 2, p. 239, doi. 10.1111/hiv.13728
    By:
    • Stephan, Christoph;
    • Spinner, Christoph D.;
    • Rieke, Ansgar;
    • Christensen, Stefan;
    • Mauss, Stefan;
    • Schreiber, Sandra;
    • Albuquerque, Boris;
    • Heinzkill, Marion;
    • Ramroth, Heribert;
    • Stellbrink, Hans‐Jürgen
    Publication type:
    Article
    49
    50

    Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study.

    Published in:
    HIV Medicine, 2024, v. 25, n. 9, p. 1030, doi. 10.1111/hiv.13659
    By:
    • Busca‐Arenzana, C.;
    • Ortega‐González, D.;
    • Díaz‐Almirón, M.;
    • Montes, M. L.;
    • Martin‐Carbonero, Luz;
    • Mican, R.;
    • Montejano, R.;
    • Ramos‐Ruperto, L.;
    • Valencia, Eulalia;
    • Delgado‐Hierro, Ana;
    • Bernardino, Jose I.
    Publication type:
    Article